Adrenergic Receptor Polymorphisms and Prevention of Ventricular Arrhythmias With Bucindolol in Patients With Chronic Heart Failure

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation: Arrhythmia and Electrophysiology

• Publication date

  2013-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCEP.111.969618PMID 23275278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Heart Failure: a Companion to Braunwald's Heart Disease

  2014cited by this paper
• Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms

  2012influential reference
• Temporal analysis of mRNA and miRNA expression in transgenic mice overexpressing Arg- and Gly389 polymorphic variants of the β1-adrenergic receptor.

  2011cited by this paper
• An &agr;2C-Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the &bgr;-Blocker Bucindolol in Chronic Heart Failure

  2010cited by this paper
• Pharmacogenetics--tailoring treatment for the outliers.

  2009cited by this paper
• Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol.

  2008cited by this paper
• Competing Risks: A Practical Perspective

  2006cited by this paper
• A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure

  2006cited by this paper
• A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.

  2006influential reference
• Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).

  2005cited by this paper
• Effect of Baseline or Changes in Adrenergic Activity on Clinical Outcomes in the &bgr;-Blocker Evaluation of Survival Trial

  2004cited by this paper
• Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON)

  2003cited by this paper
• An evaluation of the beta‐1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT‐HF sub‐study

  2003cited by this paper
• β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure

  2003cited by this paper
• Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 β1‐adrenoceptors versus Gly389 β1‐adrenoceptors in isolated human atrial myocardium

  2003cited by this paper
• Feedback Inhibition of Catecholamine Release by Two Different &agr;2-Adrenoceptor Subtypes Prevents Progression of Heart Failure

  2002cited by this paper
• A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

  2001cited by this paper
• Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study.

  2001cited by this paper
• A TRIAL OF THE BETA-BLOCKER BUCINDOLOL IN PATIENTS WITH ADVANCED CHRONIC HEART FAILURE

  2001cited by this paper
• A Four Amino Acid Deletion Polymorphism in the Third Intracellular Loop of the Human α2C-Adrenergic Receptor Confers Impaired Coupling to Multiple Effectors*

  2000cited by this paper
• Sample size considerations for the evaluation of prognostic factors in survival analysis.

  2000cited by this paper
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.

  1999cited by this paper
• Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

  1999cited by this paper
• A Gain-of-function Polymorphism in a G-protein Coupling Domain of the Human β1-Adrenergic Receptor*

  1999cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Two functionally distinct α2-adrenergic receptors regulate sympathetic neurotransmission

  1999cited by this paper
• Extending SAS Survival Analysis Techniques for Medical Research

  1997cited by this paper
• Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability.

  1995cited by this paper
• Design of the Beta-Blocker Evaluation Survival Trial (BEST). The BEST Steering Committee.

  1995cited by this paper
• The Clinical Perspective

  1994cited by this paper
• Diverse mechanisms of unexpected cardiac arrest in advanced heart failure.

  1989cited by this paper

• β1- and β2-adrenergic Receptor Haplotypes Regulate Therapeutic Responses to Placebo and the Biased Ligand β-blocker Bucindolol

  2025cites this paper
• Symptoms Burden as a Clinical Outcomes Assessment in Heart Failure Patients With Atrial Fibrillation.

  2024cites this paper
• Beta-Blocker in Heart Rate Control and Cardio Protection: The Role of ADRB1 Variants and HCN4 Regulation – A Systematic Review

  2024influential citation
• The Genetic Factors Influencing Cardiomyopathies and Heart Failure across the Allele Frequency Spectrum

  2024cites this paper
• Genetics and Pharmacogenetics of Atrial Fibrillation

  2024cites this paper
• Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology

  2021cites this paper
• β1‐receptor polymorphisms and junctional ectopic tachycardia in children after cardiac surgery

  2021cites this paper
• Advances in the Genetics and Genomics of Heart Failure

  2020cites this paper
• Adrenergic Receptor Signaling in Heart Failure

  2020cites this paper
• Pharmacogenomics in Cardiovascular Diseases

  2020cites this paper
• Pharmacogenetic factors affecting β-blocker metabolism and response

  2020cites this paper
• Pharmacogenetics in Cardiovascular Diseases

  2019cites this paper
• Overview of the impact β1-adrenergic receptor gene polymorphisms have on the progression of heart failure

  2019cites this paper
• How much is enough?

  2018cites this paper
• Dose Response of &bgr;-Blockers in Adrenergic Receptor Polymorphism Genotypes

  2018cites this paper
• Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients

  2017cites this paper
• Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments

  2017cites this paper
• Personalized Medicine in Cardiovascular Disease

  2017cites this paper
• Предикторы неблагоприятного ремоделирования левого желудочка у пациентов, перенесших инфаркт миокарда

  2017cites this paper
• Cardiovascular pharmacogenetics: a promise for genomically‐guided therapy and personalized medicine

  2017cites this paper
• &bgr;‐blocker dosage and outcomes after acute coronary syndrome

  2017cites this paper
• Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure

  2017cites this paper
• Pharmacogenomics of heart failure: a systematic review.

  2016cites this paper
• Hypertension pharmacogenomics: in search of personalized treatment approaches

  2016cites this paper
• Epigenetics, Ethnicity, Bioinformatics and Nanotechnology Opening Frontiers in Cardiac Medicine

  2016cites this paper
• Pharmacogenomics of Hypertension and Heart Disease

  2015cites this paper
• Inhaled bronchodilators and the risk of tachyarrhythmias.

  2015cites this paper
• Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction.

  2015cites this paper
• Cardiovascular Pharmacogenomics: Expectations and Practical Benefits

  2014cites this paper
• Pharmacogenomics in Heart Failure: Where Are We Now and How Can We Reach Clinical Application?

  2014cites this paper
• Interpatient Variability in Dexmedetomidine Response: A Survey of the Literature

  2014cites this paper
• Race, common genetic variation, and therapeutic response disparities in heart failure.

  2014cites this paper
• Impact of Polymorphic Variants on the Molecular Pharmacology of the Two-Agonist Conformations of the Human β1-Adrenoceptor

  2013cites this paper
• Research Highlights: Adrenergic receptor pharmacogenetics in heart failure

  2013cites this paper
• β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction.

  2013cites this paper
• Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.

  2013cites this paper